Pular para o conteúdo principal

ETHNOS_APP

Início • Busca • Periódicos • Lista 0

Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings

An initial exploratory analysis of the phenomenon’s predictors and its emotional valence

Dados Bibliográficos

ID15518878
AutoresAna María Ortiz Bernal (0000-0003-3304-6497, University of Wisconsin–Madison, autor correspondente), Charles L Raison (0000-0001-6687-0066, University of Wisconsin–Madison), Rafaelle L Lancelotta (0000-0002-7789-3463, The Ohio State University), Rafael L Lancelotta, A K Davis (0000-0003-4770-8893, The Ohio State University)
Ano2022
Volume13
Páginas1049643-1049643
Data de publicação2022-11-29
Peer ReviewedSim
Open AccessSim
TipoARTICLE
PeriódicoFrontiers in Psychiatry (JOURNAL)
Identificadores do periódicoISSN: 1664-0640 • E-ISSN: 1664-0640
EditoraFrontiers Media (PUBLISHER • CH)
DOI10.3389/fpsyt.2022.1049643
PMID36523876
OpenAlexW4310207667
IdiomaEN
Citações recebidas5
Referências citadas64

These findings suggest that reactivation phenomena, in this particular sample may most often represent a neutral or positive byproduct of the acute 5-MeO-DMT experience. More information is needed to best identify individuals most likely to experience a reactivation as a negative event to prevent such potential challenging outcomes

Descriptive statistics · Developmental psychology · Logistic regression · Phenomenon · Valence (chemistry · Clinical Psychology · Forensic Toxicology and Drug Analysis · Medicine · Neurotransmitter Receptor Influence on Behavior · Psychedelics and Drug Studies · Psychology · Internal Medicine

  • MeO-DMT for post-traumatic stress disorder

    Open Access•Anya Ragnhildstveit, Ryan Khan et al.•Frontiers in Psychiatry•2023

  • Reactivations Associated with the Use of 5-MeO-DMT Among Spanish-Speaking Individuals

    Ana María Ortiz Bernal, Charles L Raison et al.•Journal of Psychoactive Drugs•2025

  • The Epidemiology of Psychedelic Use Among United States Military Veterans

    Open Access•A K Davis, Mark J Bates et al.•Journal of Psychoactive Drugs•2024

  • Epidemiology of classic psychedelic substances

    Open Access•Tor-Morten Kvam, M V Uthaug et al.•Frontiers in Psychiatry•2023

  • A Scoping Review of Research in Naturalistic Studies with Psychedelics

    Open Access•Laura C Carvalho, Jorge Encantado et al.•Journal of Psychoactive Drugs•2025

  • Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer

    Open Access•Roland R Griffiths, Matthew W Johnson et al.•Journal of Psychopharmacology•2016

  • Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction

    Open Access•Matthew W Johnson, Albert Garcia-Romeu et al.•Journal of Psychopharmacology•2014

  • Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder

    Michael P Bogenschutz, Stephen Ross et al.•JAMA Psychiatry•2022

  • Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

    Open Access•Frederick S Barrett, Matthew W Johnson et al.•Journal of Psychopharmacology•2015

  • Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction

    Albert Garcia-Romeu, Albert Garcia‐Romeu et al.•Current Drug Abuse Reviewse•2015

  • Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

    Open Access•Robin Carhart‐Harris, Robin L Carhart-Harris et al.•Proceedings of the National…•2012

  • Ego-Dissolution and Psychedelics

    Open Access•Matthew M Nour, Lisa Evans et al.•Frontiers in Human Neuroscience•2016

  • Recall bias in epidemiologic studies

    Open Access•Steven S Coughlin•Journal of Clinical Epidemiology•1990

  • Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

    Open Access•Roland R Griffiths, William A Richards et al.•Psychopharmacology•2006

  • Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

    Charles S Grob, Alicia Danforth et al.•Archives of General Psychiatry•2011

  • Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

    Open Access•A K Davis, Frederick S Barrett et al.•JAMA Psychiatry•2021

  • Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer

    Open Access•Stephen Ro, Stephen Ross et al.•Journal of Psychopharmacology•2016

  • Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

    Open Access•RR Griffiths, R R Griffiths et al.•Journal of Psychopharmacology•2008

  • The entropic brain

    Open Access•Robin L Carhart-Harris, Robert Leech et al.•Frontiers in Human Neuroscience•2014

  • Long-term follow-up of psilocybin-facilitated smoking cessation

    Matthew W Johnson, Albert Garcia-Romeu et al.•The American Journal of Drug and…•2017

  • Psilocybin with psychological support for treatment-resistant depression

    Open Access•Robin L Carhart-Harris, Mark Bolstridge et al.•The Lancet Psychiatry•2016

  • Psilocybin occasioned mystical-type experiences

    Open Access•Roland R Griffiths, Matthew W Johnson et al.•Psychopharmacology•2011

  • The Satisfaction With Life Scale

    Ed Diener, Robert A Emmons et al.•Journal of Personality Assessment•1985

  • Examining psychological inflexibility as a transdiagnostic process across psychological disorders

    Open Access•Michael E Levin, Chelsea Maclane et al.•Journal of Contextual Behavioral…•2014

  • The use of the psychological flexibility model to support psychedelic assisted therapy

    Open Access•Rosalind Watts, Jason B Luoma•Journal of Contextual Behavioral…•2019

  • Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety

    Open Access•A K Davis, Frederick S Barrett et al.•Journal of Contextual Behavioral…•2019

  • Bufo alvarius

    Open Access•Andrew Weil, Andrew T Weil et al.•Journal of Ethnopharmacology•1994

  • Pharmepéna-Psychonautics

    Jonathan Ott•Journal of Psychoactive Drugs•2001

  • Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users

    Rafaelle L Lancelotta, Rafael L Lancelotta et al.•Journal of Psychoactive Drugs•2020

  • Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression

    Open Access•Rosalind Watts, Camilla Day et al.•Journal of Humanistic Psychology•2017

  • A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting

    Open Access•M V Uthaug, R Lancelotta et al.•Journal of Psychedelic Studies•2020

Obras citantes distintas5
Citações por ano1,67
Intervalo de citações2023 - 2025 (3)
Velocidade de citaçãorecent
Altamente citadoNão
Tipos de citaçãoNeutras: 5
Ethnos_APP • Projeto Open Source • Licença MIT • Frontend v2.0.0 • Privacidade e Cookies • Documentação da API: api.ethnos.app/docs • Código da API: GitHub • DOI: 10.5281/zenodo.17049435 • Código do Frontend: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae